| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PA1 |
| Uniprot No | Q9BTK6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-254aa |
| 氨基酸序列 | MSLARGHGDTAASTAAPLSEEGEVTSGLQALAVEDTGGPSASAGKAEDEGEGGREETEREGSGGEEAQGEVPSAGGEEPAEEDSEDWCVPCSDEEVELPADGQPWMPPPSEIQRLYELLAAHGTLELQAEILPRRPPTPEAQSEEERSDEEPEAKEEEEEKPHMPTEFDFDDEPVTPKDSLIDRRRTPGSSARSQKREARLDKVLSDMKRHKKLEEQILRTGRDLFSLDSEDPSPASPPLRSSGSSLFPRQRKY |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4条关于PA1重组蛋白的模拟参考文献示例(实际文献需通过学术数据库检索获取)：
---
1. **文献名称**：*Expression and Purification of Recombinant PA1 Protein from Bacillus anthracis*
**作者**：Smith J. et al.
**摘要**：研究通过大肠杆菌表达系统成功克隆并纯化了炭疽杆菌PA1重组蛋白，优化了表达条件并验证其与宿主细胞受体的结合活性。
2. **文献名称**：*Structural Analysis of PA1 Domain in Cancer Cell Adhesion*
**作者**：Li X. et al.
**摘要**：解析了重组PA1蛋白的晶体结构，发现其通过特定结构域促进肿瘤细胞黏附和迁移，为靶向治疗提供了分子基础。
3. **文献名称**：*PA1 as a Protective Antigen in Vaccine Development*
**作者**：Garcia R. et al.
**摘要**：在小鼠模型中评估了重组PA1蛋白的免疫原性，证明其可诱导高水平中和抗体，显著提高对病原体的保护效力。
4. **文献名称**：*Functional Characterization of PA1 in Extracellular Matrix Remodeling*
**作者**：Wang Y. et al.
**摘要**：利用重组PA1蛋白研究其在细胞外基质降解中的作用，揭示了其通过调控金属蛋白酶活性影响组织修复的机制。
---
**注意**：以上文献为模拟生成，实际研究中需通过PubMed、Google Scholar等平台检索真实文献(关键词如“recombinant PA1 protein”“Protective Antigen PA1”)。PA1可能指向不同领域(如炭疽保护性抗原、前列腺抗原等)，建议结合具体研究背景筛选。
PA1 recombinant protein is a genetically engineered protein derived from the PA1 antigen, a molecule implicated in various cellular processes and disease pathways. Originally identified for its association with cancer biology, PA1 has drawn attention due to its potential role in cell proliferation, apoptosis regulation, and immune modulation. The recombinant form is produced using heterologous expression systems, such as *E. coli* or mammalian cell cultures, enabling scalable production with high purity for research and therapeutic applications.
Structurally, PA1 typically contains functional domains critical for ligand binding or enzymatic activity, depending on its native biological context. Its recombinant version retains these features, allowing scientists to study its interactions, post-translational modifications, and signaling mechanisms in controlled settings. This protein has become a valuable tool in cancer research, particularly in exploring tumor microenvironment dynamics, metastasis, and resistance mechanisms. Additionally, PA1's involvement in inflammatory and autoimmune disorders has expanded its relevance to immunology studies.
In drug development, PA1 recombinant protein serves as a target for monoclonal antibody validation, small-molecule inhibitor screening, and vaccine design. Its use in diagnostic assays, such as ELISA or immunohistochemistry, aids in biomarker discovery and disease stratification. Challenges in its application include maintaining structural stability during production and addressing potential immunogenicity in therapeutic contexts. Ongoing research focuses on optimizing expression systems, engineering variants with enhanced functionality, and elucidating its pleiotropic roles in health and disease. As a versatile biological reagent, PA1 recombinant protein continues to support advances in molecular biology and precision medicine.
×
